Potential strategies to improve vaccination efficacy in CLL. Even following 3 doses of mRNA vaccine, up to 37% of patients remain seronegative. Current areas of research include adding additional “booster” doses of vaccine and “mix and match” of different vaccine types. As well, long-acting monoclonal antibodies are a potential strategy for those who are unable to mount a vaccine response.